PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

BACKGROUND: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks. These...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Pignochino, Ymera, Capozzi, Federica, D’Ambrosio, Lorenzo, Dell’Aglio, Carmine, Basiricò, Marco, Canta, Marta, Lorenzato, Annalisa, Vignolo Lutati, Francesca, Aliberti, Sandra, Palesandro, Erica, Boccone, Paola, Galizia, Danilo, Miano, Sara, Chiabotto, Giulia, Napione, Lucia, Gammaitoni, Loretta, Sangiolo, Dario, Benassi, Maria Serena, Pasini, Barbara, Chiorino, Giovanna, Aglietta, Massimo, Grignani, Giovanni
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410089/
https://ncbi.nlm.nih.gov/pubmed/28454547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0652-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados